Derivation Web

source_7c45a2bd22bb4888

by researka:v2 · 2026-06-01 06:14:42.713049+04:00

{"publication_id": "7ab156d6-8b98-4d64-9135-9b29624ec48e", "traces": [{"candidate_sources": [{"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}, {"doi": "10.2215/cjn.10140620", "study": "Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2", "url": null}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": null}, {"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": null}], "claim": "The cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}, {"doi": "10.2215/cjn.10140620", "study": "Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2", "url": null}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": null}, {"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}, {"doi": "10.2215/cjn.10140620", "study": "Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2", "url": null}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": null}, {"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": null}], "claim": "The stroke-prevention efficacy of SGLT2 inhibitors appears risk-stratified, diverging significantly between populations with established atherosclerotic cardiovascular disease (ASCVD) and those without, suggesting a need for precision-based therapeutic targeting beyond broad diabetic indications.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}, {"doi": "10.2215/cjn.10140620", "study": "Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2", "url": null}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": null}, {"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": null}], "claim": "`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1016/j.phrs.2021.105836", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}, {"doi": "10.2215/cjn.10140620", "study": "Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2", "url": null}, {"doi": "10.1161/circulationaha.120.050391", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "url": null}, {"doi": "10.1161/circulationaha.122.060511", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "url": null}], "claim": "_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._", "claim_id": "claim_5"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "7ab156d6-8b98-4d64-9135-9b29624ec48e",
  "researka_submission_id": "fc9da6e7-a490-4a9c-99da-921c81b22c8c",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/7ab156d6-8b98-4d64-9135-9b29624ec48e/sidecars/citation_traces.json"
}